GERN
GERON CORP
NASDAQ · Healthcare · Biotechnology · US
$1.20
+2.56%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$1.20
From 52W high−38.46%
Volume4.88M
Market cap$770.97M
P/E (TTM)—
P/S (TTM)3.8x
Div yield—
Key dataOct 19, 2026
Open
$1.20
From 52W high
−38.46%
Volume
4.88M
Market cap
$770.97M
ValuationView details →
P/E (Fwd)
25.0x
EV/EBITDA
−14.3x
P/E (TTM)
—
RSI (14)
40.5
MomentumView details →
1D Return
+2.56%
YTD Return
−9.09%
SummaryUpdated Jun 1, 2026
Geron Corporation (NASDAQ:GERN) is a late-stage clinical biopharmaceutical company founded in 1990 and headquartered in Foster City, California. The company went public in 1996 and has focused its efforts on developing therapeutics for blood cancers, specifically myeloid hematologic malignancies. After decades of research and development, Geron achieved a significant milestone in June 2024 with the FDA approval of its lead drug candidate, imetelstat, which is now marketed under the brand name <b>RYTELO</b>. The company has transitioned from a purely clinical-stage entity to a commercial organization with its first approved product generating revenue.
Similar companies
Latest newsMore news →
GERON CORP granted stock options to three newly hired employees to purchase an aggregate of 570,000 common shares as an inducement to accept employment.10h agoGERON CORP announced two oral presentations and one poster presentation on imetelstat in patients with lower-risk myelodysplastic syndromes at hematology meetings in Japan and the German-speaking region.8d agoGeron Corporation granted stock options to purchase an aggregate of 821,250 shares of common stock to nine newly hired employees as an inducement to their acceptance of employment, effective September 17, 2026.31d ago